 | • レポートコード：STR-DC031 • 出版社/出版日：Straits Research / 2019年11月28日 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療機器 |
| Single User（1名様用、印刷不可） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User（5名様用） | ￥836,200 (USD5,650) | ▷ お問い合わせ |
| Enterprise Price（法人閲覧用） | ￥1,073,000 (USD7,250) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートでは、心筋梗塞の世界市場について調査・分析し、調査手法、市場概要、種類別（鎮痛薬、抗血小板薬、血管拡張薬、血栓溶解薬および抗血栓薬、糖タンパク質IIb / IIIa阻害薬、Βアドレナリン遮断薬、アンジオテンシン受容体拮抗薬、アンジオテンシン変換酵素阻害薬）分析、流通チャンネル別（病院、病院薬局、ドラッグストア、オンラインドラッグストア）分析、地域別分析、企業概要などを含め次の構成でお届け致します。 ・イントロダクション ・調査手法 ・市場概要 ・心筋梗塞の世界市場：種類別（鎮痛薬、抗血小板薬、血管拡張薬、血栓溶解薬および抗血栓薬、糖タンパク質IIb / IIIa阻害薬、Βアドレナリン遮断薬、アンジオテンシン受容体拮抗薬、アンジオテンシン変換酵素阻害薬） ・心筋梗塞の世界市場：流通チャンネル別（病院、病院薬局、ドラッグストア、オンラインドラッグストア） ・心筋梗塞の世界市場：地域別 ・企業概要 |
Global myocardial infarction market was valued at USD 1,530.7 million in 2018, growing at a CAGR of 8.0% during the forecast period of 2019–2026.
Myocardial (MI) is a medical term for a heart attack. It occurs when blood supply from the coronary artery to the heart muscle gets blocked due to plaque buildup—the substance made up of cholesterol and fats. Sudden chest pain, shortness of breath, anxiety, and sweating are some of the most of common symptoms of MI. People with high blood pressure, obesity, diabetes, smoking addiction, and family history with heart attacks are more prone to myocardial infarction. Moreover, rising incidences of coronary artery diseases and changing lifestyle are the major contributors to the growing incidence of such as diseases. Electrocardiogram, blood tests, and coronary angiogram are few major diagnostic tests used for detection of the MI.
Increasing prevalence of cardiovascular diseases, obesity, and diabetes
According to American Heart Association (2018), 92.1 million Americans suffered from cardiovascular diseases. Cardiovascular diseases include coronary heart disease, rheumatic heart disease, and others. The most common was the coronary heart disease, which caused 43.8% deaths in the U.S. According to the Centre for Disease Control & Prevention (CDC) 2016, Women with diabetes have a 40% more risk of developing heart diseases and a 25% more risk of stroke than men with diabetes. People with diabetes are twice as likely to have MI because diabetic people have higher cholesterol & triglycerides leading to higher chance of MI.
Segmental Insights
For a better understanding of the global myocardial infarction market, we have segmented the market by Product Type, and distribution channel.
By Product Type, the market is segmented into analgesics, antiplatelet agents, vasodilators, thrombolytics and anti-thrombotic agents, glycoprotein IIB/IIIA inhibitors, β adrenergic blockers, other. Analgesics is accounting for the largest share of the market. Analgesics are the medicine used to reduce pain. They act differently on peripheral & central nervous system. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are a specific class of analgesic that inhibit COX enzymes and reduces pain by reducing inflammation. According to the FDA, NSAIDs can increase the risk of myocardial infarction & strokes. Therefore, they are properly labeled. These drugs are available as over the counter as well as prescription.
Regional Insights
Global Myocardial Infarction market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is dominating the market and accounted for the highest share in the forecast period. Increasing prevalence of cardiovascular diseases in the U.S is expected to drive the growth of the market. For instance, according to the Centre for Disease Control and Prevention (CDC), every 40 second someone gets diagnosed with myocardial infarction in the U.S. Additionally, according to American Heart Association (AHA) 2018, about 92.1 million adult Americans are living with cardiovascular diseases. These are causing more deaths than all forms of cancers and chronic respiratory diseases each year. Coronary artery disease is the leading cause of myocardial infarction, which accounts for 43.8% of deaths in the U.S. The overall prevalence of MI in the U.S is 3%. Additionally, lack of physical activity is also raising the risk of MI, and it is estimated that about 30.4% of the U.S adults do not engage themselves in any form of physical activity. Mexico is expected to emerge as slow growing market at country level owing to low government spending on healthcare and a smaller number of health workers. Additionally, it has low rates of daily smoking and alcohol consumption.
Europe is second leading region in the forecast period owing presence of leading pharmaceutical companies in the region. AstraZencea, one of the leading pharmaceutical companies, launched an app ‘Day by Day’ in partnership with mobile health enabled company Vida in 2015 and with collaboration with Duke University it helps patients to recover from the trauma of heart attack. The app provides coaching for the speedy recovery and also provide educational videos and food journals to patients.
Middle East & Africa is offering various lucrative opportunities for the market. Recently, a steep rise in the heart-related problems have been witnessed in South Africa due to growing obesity, drinking habit, inactive lifestyle, and a high number of smokers. A third of South Africans have high blood pressure, which can lead to myocardial infarction or heart failure. Additionally, hypertension is the major cause for MI. To combat this, South African heart association has provided the specific diet guidelines to the population. Thus, it expected to provide lucrative opportunities to the market players to expand their reach in this region to meet the increasing demand for myocardial Infarction treatment.
Key Players
Some of the prominent players in the market are Apotex Inc., AstraZeneca, Bayer AG, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Mylan N.V., Novartis AG, Par Pharmaceutical Companies, Inc., and Pfizer Inc.
TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Myocardial Infarction Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
3.6 Heart Failure
3.5.1 Types of Heart Failure
3.5.1.1 Acute
3.51.2 Chronic
3.5.2 Comparative Study of Myocardial Infarction and Heart Failure
3.5.2.1 Medication
3.5.2.2 Surgical Procedure
4 Type Overview
4.1 Introduction
4.1.1 Market Size & Forecast
4.2 Analgesics
4.3 Antiplatelet agents
4.4 Vasodilators
4.5 Thrombolytics and anti-thrombotic agents
4.6 Glycoprotein IIb/IIIa inhibitors
4.7 Β adrenergic blockers
4.8 Angiotensin receptor antagonists
4.9 Angiotensin converting enzyme inhibitors
5 Distribution Channel Overview
5.1 Introduction
5.1.1 Market Size & Forecast
5.2 Hospitals
5.3 Hospital Pharmacies
5.4 Drug Stores
5.5 Online drug stores
6 Regional Overview
6.1 Introduction
6.1.1 Market Size & Forecast
6.2 America
6.2.1 North America
6.2.1.1 U.S.
6.2.1.1.1 By Type
6.2.1.1.2 By Distribution Channel
6.2.1.2 Canada
6.2.1.2.1 By Type
6.2.1.2.2 By Distribution Channel
6.2.1.3 Mexico
6.2.1.3.1 By Type
6.2.1.3.2 By Distribution Channel
6.2.2 South America
6.2.2.1 By Type
6.2.2.2 By Distribution Channel
6.3 Europe
6.3.1 Market Size & Forecast (Value)
6.3.2 Western Europe
6.3.2.1 Germany
6.3.2.1.1 By Type
6.3.2.1.2 By Distribution Channel
6.3.2.2 France
6.3.2.2.1 By Type
6.3.2.2.2 By Distribution Channel
6.3.2.3 U.K.
6.3.2.3.1 By Type
6.3.2.3.2 By Distribution Channel
6.3.2.4 Italy
6.3.2.4.1 By Type
6.3.2.4.2 By Distribution Channel
6.3.2.5 Spain
6.3.2.5.1 By Type
6.3.2.5.2 By Distribution Channel
6.3.2.6 Rest of Western Europe
6.3.2.6.1 By Type
6.3.2.6.2 By Distribution Channel
6.3.3 Eastern Europe
6.4 Asia Pacific
6.4.1 Market Size & Forecast (Value)
6.4.2 China
6.4.2.1 By Type
6.4.2.2 By Distribution Channel
6.4.3 India
6.4.3.1 By Type
6.4.3.2 By Distribution Channel
6.4.4 Japan
6.4.4.1 By Type
6.4.4.2 By Distribution Channel
6.4.5 South Korea
6.4.5.1 By Type
6.4.5.2 By Distribution Channel
6.4.6 Australia
6.4.6.1 By Type
6.4.6.2 By Distribution Channel
6.4.6 Rest of Asia-Pacific
6.4.7.1 By Type
6.4.7.2 By Distribution Channel
6.5 Middle East
6.5.1 Market Size & Forecast (Value)
6.5.2 The Middle East
6.5.2.1 UAE
6.5.2.2.1 By Type
6.5.2.2.2 By Distribution Channel
6.5.2.2 Qatar
6.5.2.2.1 By Type
6.5.2.2.2 By Distribution Channel
6.5.2.3 Rest of Middle East
6.5.2.3.1 By Type
6.5.2.3 2 By Distribution Channel
6.6 Africa
6.6.1 Market Size & Forecast (Value)
6.6.2 South Africa
6.6.2.1 South Africa
6.6.2.1.1 By Type
6.6.2.1.2 By Distribution Channel
6.6.2.2 Ghana
6.6.2.2.1 By Type
6.6.2.2.2 By Distribution Channel
6.6.2.3 Nigeria
6.6.2.3.1 By Type
6.6.2.3.2 By Distribution Channel
6.6.2.4 Rest of Africa
6.6.2.4.1 By Type
6.6.2.4 2 By Distribution Channel
7. Company Profile
7.1 Apotex Inc
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Recent Developments
7.1.4 Product Portfolio
7.2 AstraZeneca
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Recent Developments
7.2.4 Product Portfolio
7.3 Bayer AG
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Recent Developments
7.3.4 Product Portfolio
7.4 Boehringer-Ingelheim
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Recent Developments
7.4.4 Product Portfolio
7.5 Bristol-Myers Squibb Company
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Recent Developments
7.5.4 Product Portfolio
7.6 Daiichi Sankyo Co., Ltd.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Recent Developments
7.6.4 Product Portfolio
7.7 Mylan N.V.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Recent Developments
7.7.4 Product Portfolio
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Recent Developments
7.8.4 Product Portfolio
7.9 Par Pharmaceutical Companies, Inc.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Recent Developments
7.9.4 Product Portfolio
TABLE 1 Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 2 Analgesics Myocardial Infarction Market Share, By Region, 2016-2026 ($ Million)
TABLE 3 Antiplatelet agents Myocardial Infarction Market Share, By Region, 2016-2026, ($ Million)
TABLE 4 Vasodilators Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 5 Thrombolytics and anti-thrombotic agents Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 6 Glycoprotein IIb/IIIa inhibitors Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 7 Β adrenergic blockers Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 8 Angiotensin receptor antagonists Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 9 Angiotensin converting enzyme inhibitors Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 10 Myocardial Infarction Market Share Value, 2016-2026 ($Million)
TABLE 11 Myocardial Infarction Market Share, By Region, 2016-2026 ($ Million)
TABLE 12 America Myocardial Infarction Market Share Value, By Region, 2016-2026 ($Million)
TABLE 13 America Myocardial Infarction Market Share value, By Type, 2016-2026 ($Million)
TABLE 14 America Myocardial Infarction Market Share value, By Functions, 2016-2026 ($Million)
TABLE 15 U.S. Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 16 U.S. Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 17 Canada Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 18 Canada Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 19 Mexico Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 20 Mexico Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 21 South America Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 22 South America Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 23 Europe Myocardial Infarction Market Share Value, By Region, 2016-2026 ($Million)
TABLE 24 Europe Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 25 Europe Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 26 Western Europe Myocardial Infarction Market Share Value, By Country, 2016-2026 ($Million)
TABLE 27 Western Europe Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 28 Western Europe Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 29 Germany Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 30 Germany Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 31 France Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 32 France Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 33 UK Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 34 UK Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 35 Italy Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 36 Italy Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 37 Spain Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 38 Spain Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 39 Rest of Western Europe Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 40 Rest of Western Europe Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 41 Eastern Europe Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 42 Eastern Europe Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 43 Asia-Pacific Myocardial Infarction Market Share, By Country, 2016-2026 ($Million)
TABLE 44 Asia-Pacific Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 45 Asia-Pacific Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 46 Japan Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 47 Japan Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 48 China Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 49 China Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 50 Australia Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 51 Australia Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 52 India Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 53 India Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 54 South Korea Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 55 South Korea Myocardial Infarction Market Share, By Functions 2016-2026 ($Million)
TABLE 56 Rest of Asia-pacific Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 57 Rest of Asia-pacific Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 58 The Middle East and Africa Myocardial Infarction Market Share, By Region, 2016-2026 ($Million)
TABLE 59 The Middle East and Africa Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 60 The Middle East and Africa Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 61 The Middle East Myocardial Infarction Market Share, By Country, 2016-2026 ($Million)
TABLE 62 The Middle East Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 63 The Middle East Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 64 Saudi Arabia Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 65 Saudi Arabia Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 66 UAE Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 67 UAE Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 68 Qatar Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 69 Qatar Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
TABLE 70 Africa Myocardial Infarction Market Share, By Country, 2016-2026 ($Million)
TABLE 71 Africa Myocardial Infarction Market Share, By Type, 2016-2026 ($Million)
TABLE 72 Africa Myocardial Infarction Market Share, By Functions, 2016-2026 ($Million)
List of Figures
FIGURE 1 Myocardial Infarction Market Overview
FIGURE 2 Value Chain Analysis
FIGURE 3 Bargaining Power of Suppliers
FIGURE 4 Bargaining Power of Buyers
FIGURE 5 Threat of Substitutes
FIGURE 6 Threat of New Entrants
FIGURE 7 Competitive Rivalry
FIGURE 8 Myocardial Infarction Market, 2016-2026
FIGURE 9 U.S. Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 10 Canada Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 11 Mexico Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 12 South America Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 13 Western Europe Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 14 Germany Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 15 France Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 16 UK Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 17 Italy Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 18 Spain Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 19 Rest of Western Europe Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 20 Eastern Europe Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 21 Japan Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 22 China Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 23 Australia Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 24 India Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 25 South Korea Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 26 Rest of Asia-pacific Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 27 The Middle East Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 28 Saudi Arabia Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 29 UAE Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 30 Qatar Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 31 Rest of The Middle East Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 32 Africa Myocardial Infarction Market Share, 2016-2026 ($Million)
FIGURE 33 Apotex Inc: Revenue Analysis, ($ million)
FIGURE 34 Apotex Inc: Segment Revenue 2018 (%)